- ICU
intensive care unit
- MCT
medium-chain TAG
Fatty acids
Fatty acids are hydrocarbon chains with a carboxyl group at one end and a methyl group at the other end(Reference Calder, Burdge, Nicolaou and Kafatos1). The carboxyl group is reactive and readily forms ester links with alcohol groups, e.g. those on glycerol or cholesterol, in turn forming acylglycerols (e.g. TAG, phospholipids) and cholesteryl esters. Fatty acid chain lengths vary from 2 to ≥30 and the chain may contain double bonds. Fatty acids containing double bonds in the hydrocarbon chain are referred to as unsaturated fatty acids; a fatty acid containing one double bond is termed a MUFA while one containing two or more double bonds is termed a PUFA. Fatty acids have common names (Table 1) and systematic names. They are also referred to by a shorthand nomenclature that denotes the number of C in the chain, the number of double bonds and the position of the first double bond relative to the methyl-C (n; also termed ω; Table 1). n-3, n-6 and n-9 Fatty acids are so-called because the first double bond is on C-3, -6 or -9 respectively, counting the methyl-C as C-1. The simplest n-6 fatty acid is linoleic acid (18:2n-6) and the simplest n-3 fatty acid is α-linolenic acid (18:3n-3). Linoleic and α-linolenic acids cannot be synthesised in animals, including man. They are the classical essential fatty acids. In contrast, SFA and MUFA can be synthesised de novo in human subjects(Reference Gurr, Harwood and Frayn2).
Table 1. Common names, shorthand nomenclature and sources of fatty acids used in parenteral lipid emulsions
Although mammalian cells cannot synthesise linoleic and α-linolenic acids, they can metabolise them by further desaturation and elongation. Linoleic acid can be converted to γ-linolenic (18:3n-6), then to dihomo-γ-linolenic acid (20:3n-6) and then to arachidonic acid (20:4n-6). Using the same series of enzymes α-linolenic acid is converted to EPA (20:5n-3). A complex pathway for further conversion of EPA to DHA (22:6n-3) exists(Reference Calder, Burdge, Nicolaou and Kafatos1–Reference Sprecher3). Fatty acids that are important in parenteral nutrition and their sources are listed in Table 1.
Desirable properties for lipids to be used in parenteral nutrition
Lipids used in parenteral nutrition should provide:
a source of energy as an alternative to glucose;
building blocks, since patients requiring parenteral nutrition will be undergoing processes involving cell replication and tissue repair;
essential fatty acids in order that deficiency symptoms are avoided;
a ‘good’ fatty acid balance, although the precise definition of this balance is still lacking;
fatty acids with desirable biological activities.
Lipids were first introduced into parenteral nutrition formulas in the 1960s in order to provide a more balanced supply of energy, along with glucose(Reference Edgren and Wrtelind4–Reference Wretlind6). The lipid typically used in parenteral nutrition is soyabean oil, in which linoleic acid comprises about 50% of the fatty acids present. Soyabean oil lipid emulsions include: Intralipid® (Fresenius Kabi, Bad Homberg, Germany); Lipovenoes® (Fresenius Kabi); Lipofundin® (B Braun, Melsugen, Germany); Ivelip® (Baxter Healthcare, Maurepas, France).
A meta-analysis of total parenteral nutrition has suggested that inclusion of lipids might be detrimental (lipids v. no lipids; P=0·09)(Reference Heyland, MacDonald and Keefe7), at least in very-ill patients; most of the studies included in the meta-analysis used soyabean oil-based lipid emulsions. A study in patients following major gastrointestinal surgery has identified that the amount of n-6 PUFA (i.e. linoleic acid) infused is one of two predictors of the length of hospital stay (increased by 1·6 d/100 g n-6 PUFA infused), the other being the delay in the onset of initiating nutritional support(Reference Koch and Heller8). A number of in vitro experiments have shown that soyabean oil-based lipid emulsions can exert immunosuppressive effects (for references, see Calder et al. (Reference Calder, Sherrington and Askanazi9)), which would clearly be detrimental in patients at risk of infection and sepsis. Clinical trials with soyabean oil-based lipid emulsions provide conflicting evidence, with some showing selective immunosuppressive effects(Reference Monson, Sedman and Ramsden10–Reference Furukawa, Yamamori and Takagi12), perhaps linked to poorer patient outcomes(Reference Battistella, Widergren and Anderson11). However, other studies do not show such effects on the immune system(Reference Dionigi, Dionigi and Prati13–Reference Sedman, Somers and Ramsden15) or on clinical outcomes(Reference Lenssen, Bruemmer and Bowden16). Details of these studies are given in Table 2(Reference Calder17). Despite the inconsistencies in the outcomes of such studies, there is a view developing that the use of lipid emulsions based entirely on soyabean oil may not be optimal or may even be harmful. The concern about potential harm, based mainly on the notion that n-6 PUFA might be ‘pro-inflammatory, immunosuppressive and pro-coagulatory’, has led to the development of alternative lipid emulsions for parenteral applications. Two alternative philosophies to reducing the amount of linoleic acid have been adopted. The first has been to simply dilute soyabean oil with another oil that is fairly inert. Examples of this strategy include the use of so-called medium-chain TAG (MCT; i.e. TAG containing predominantly medium-chain fatty acids) and the use of olive oil. The second approach has been to partially replace soyabean oil with another oil that is believed to exert benefits in its own right. An example of this strategy is the use of fish oil. Soyabean oil is often referred to as ‘long-chain TAG’, but this nomenclature is an incorrect use of this term since the lipids found in olive oil, fish oil and other oils not used in parenteral nutrition are also TAG containing long-chain fatty acids. The following lipid emulsions are available as alternatives to pure soyabean oil emulsions: Lipofundin MCT/LCT® (B Braun), a 50:50 (v/v) mixture of MCT (in the form of coconut oil) and soyabean oil; Lipovenoes MCT® (Fresenius Kabi), a 50:50 (v/v) mixture of MCT (in the form of coconut oil) and soyabean oil; Structolipid® (Fresenius Kabi), produced by inter-esterification of a 50:50 (v/v) mixture of MCT (in the form of coconut oil) and soyabean oil; ClinOleic® (Baxter Healthcare), an 80:20 (v/v) mixture of olive and soyabean oils; Lipoplus® (also known as Lipidem®; B Braun), a 50:40:10 (by vol.) mixture of coconut, soyabean and fish oils; SMOFLipid® (Fresenius Kabi), a 30:30:25:15 (by vol.) mixture of coconut, soyabean, olive and fish oils. In addition, the product Omegaven® (Fresenius Kabi), which is 100% fish oil, is available for use as a supplement to be diluted with another lipid emulsion of choice.
Table 2. Some reported immunological and clinical outcomes of studies using lipid emulsions based entirely on soyabean oil (modified from Calder(Reference Calder17))
PBMNC, peripheral blood mononuclear cells; approx, approximately.
Use of medium-chain TAG in parenteral nutrition
Emulsions containing MCT mixed with soyabean oil are well established, having been introduced in the 1980s(Reference Ulrich, McCarthy Pastores and Katz18, Reference Adolph19). Medium-chain fatty acids are: more soluble than longer-chain fatty acids and readily cleared from the circulation; easily oxidised and not stored as TAG; may be protein sparing because they are ketogenic; do not impair liver function and do not interfere with pulmonary hydrodynamics or gas exchange; resistant to peroxidation(Reference Ulrich, McCarthy Pastores and Katz18, Reference Adolph19). Studies have directly compared the effects of soyabean oil and a mixture of MCT and soyabean oil on immune function(Reference Gogos, Kalfarentzos and Zoumbos14, Reference Sedman, Somers and Ramsden15). In critically-ill patients there is no difference in numbers of various immune cells in the bloodstream but CD4+:CD8+ cells is maintained in the MCT–soyabean oil group whereas it declines in the soyabean oil group(Reference Gogos, Kalfarentzos and Zoumbos14); this finding is indicative of better maintenance of immune function in the former group. In patients post gastrointestinal surgery there are no differences in lymphocyte proliferation or IL-2 production between soyabean oil and MCT–soyabean oil groups(Reference Sedman, Somers and Ramsden15). However, natural killer cell activity is increased in the MCT–soyabean oil group. Again, this finding is suggestive of better immune function in the MCT–soyabean oil group.
Use of olive oil in parenteral nutrition
Olive oil is found in two lipid emulsions, ClinOleic and SMOFLipid. As SMOFLipid also contains fish oil, studies with this emulsion will be described in the discussion on fish oil (see later). Olive oil is an important component of the Mediterranean diet and is generally considered to be healthy(Reference Quiles, Ramirez-Tortosa and Yaqoob20). Oleic acid, a major constituent of olive oil, has little impact on immune function and is fairly resistant to peroxidation. ClinOleic does not affect lymphocyte proliferation in vitro, while soyabean oil-based emulsions are suppressive(Reference Granato, Blum and Rössle21). In vitro and animal studies using ClinOleic have been collated and reviewed(Reference Sala-Vila, Barbosa and Calder22). Trials of ClinOleic in home parenteral nutrition, in patients with burns and in critically-ill patients have now been conducted and are summarised in Table 3. Three trials in home parenteral nutrition have shown that ClinOleic is safe and well tolerated; ClinOleic has no effect on immune function, inflammatory markers, oxidative stress or routine laboratory variables(Reference Thomas-Gibson, Jawhari and Atlan23–Reference Vahedi, Atlan and Joly25). A study of the use of ClinOleic in intradialytic parenteral nutrition has revealed no difference from soyabean oil in relation to markers of inflammation and oxidative stress and an absence of adverse effects(Reference Cano, Saingra and Dupuy26). A comparison has been made of a parenteral regimen of high glucose in combination with MCT–soyabean oil and low glucose in combination with ClinOleic in patients with severe trauma in the intensive care unit (ICU)(Reference Huschak, Zur Nieden and Hoell27). The low-glucose ClinOleic group was reported to have lower blood glucose and less requirement for insulin, as would be expected, and also to exhibit a shorter duration of mechanical ventilation, fewer infections, better immune function and a shorter length of ICU stay. These findings were interpreted as being a result of the use of ClinOleic, but the study design does not allow the findings to be associated with any particular component of the nutrition. A recent study of soyabean oil v. ClinOleic in critically-ill patients (mainly patients post surgery in the ICU) has shown no differences in inflammatory markers, infections, ICU stay, hospital stay or mortality(Reference Mateu-de Antonio, Grau and Luque28). Similarly, in patients with severe burns in the ICU no difference was found between MCT–soyabean oil and ClinOleic in relation to inflammatory markers, number of infections, organ (including liver) dysfunction, duration of ICU stay, duration of hospital stay or mortality(Reference García-de-Lorenzo, Denia and Atlan29).
Table 3. Summary of clinical trials of ClinOleicFootnote * (an 80:20 (v/v) mixture of olive and soyabean oils) in adults
ICU, intensive care unit; MCT, medium-chain TAG; HLA, human leucocyte antigen.
* Baxter Healthcare, Maurepas, France.
Thus, ClinOleic is safe to use in patients receiving home parenteral nutrition. It has been used in quite small experimental studies in critically-ill patients and in patients with trauma or burns and shown to be safe and well tolerated. However, there is little evidence at this stage of advantage over soyabean oil or MCT–soyabean oil. Further larger and well-designed studies are needed using ClinOleic in target patient groups.
Fish oil in parenteral nutrition
Fish oil contains the very-long-chain n-3 PUFA EPA and DHA. There is strong evidence for health benefits of these fatty acids especially in relation to CVD(Reference Calder30–Reference Studer, Briel and Leimenstoll33). They act to modify tissue and blood lipid metabolism, blood lipid concentrations, blood coagulation, immune function, inflammation and endothelial function(Reference Wang, Harris and Chung34–Reference Calder38). EPA and DHA are readily incorporated into cells and tissues and act to modify membrane properties, eicosanoid profiles, signal transduction processes and gene expression(Reference Calder38). Through these mechanisms they result in improved cell and tissue function. Thus, using fish oil to partly replace soyabean oil in parenteral nutrition offers the possibility to both decrease the amount of linoleic acid present and to increase the amount of biologically-active n-3 PUFA(Reference Furst and Kuhn39–Reference Grimm42). Obviously, this objective is not achieved with MCT or olive oil since neither of them contains substantial amounts of n-3 PUFA.
Three lipid emulsions that include fish oil as a component are available: Omegaven; Lipoplus; SMOFLipid. Omegaven is a pure fish oil emulsion (100 g lipid/l) that will typically contain approximately 3 g EPA+DHA/100 ml. It is recommended that Omegaven is used in combination with other emulsions (e.g. those based on soyabean oil or mixtures of MCT and soyabean oil) such that Omegaven contributes 10–20% of the infused emulsion. Lipoplus (known as Lipidem is some countries) is an emulsion (200 g lipid/l) with the lipid being a mix (%, v/v) of 50 MCT, 40 soyabean oil and 10 fish oil. Each 100 ml Lipoplus will typically contain about 0·6 g EPA+DHA. SMOFLipid is an emulsion (200 g lipid/l) with the lipid being a mix (%, v/v) of 30 MCT, 30 soyabean oil, 25 olive oil and 15 fish oil. Each 100 ml SMOFLipid will typically contain about 1 g EPA+DHA.
Studies of fish oil in patients following surgery
Intravenous infusion of a lipid emulsion containing fish oil into patients for 5 d following gastrointestinal surgery results in an altered fatty acid composition of leucocytes; EPA content is increased 2·5-fold(Reference Morlion, Torwesten and Lessire43). This outcome would be expected to impact on the profile of eicosanoids produced from arachidonic acid and EPA. Indeed, several studies have demonstrated that intravenous infusion of lipid emulsions containing fish oil into patients who had undergone major gastrointestinal surgery results in lower production of arachidonic acid-derived eicosanoids and higher production of EPA-derived eicosanoids by blood leucocytes stimulated ex vivo (Reference Morlion, Torwesten and Lessire43–Reference Grimm, Mertes and Goeters46). Plasma TNFα concentrations are lower at day 6 post surgery while plasma IL-6 concentrations are lower at day 10 post surgery in patients who have undergone major gastrointestinal surgery and have then received a mix of MCT, soyabean oil and fish oil (50:30:20, by vol.; a prototype version of Lipoplus) for 5 d post surgery compared with those who have received an MCT–soyabean oil mix(Reference Wachtler, Konig and Senkal44). Clinical outcomes are not reported. A more recent study has infused Omegaven, providing 10 g fish oil/d, on the day before abdominal surgery and on days 1–5 following abdominal surgery(Reference Weiss, Meyer and Matthies47). On days 4 and 5 the patients also received standard total parenteral nutrition, which included 50 g fat as soyabean oil/d. A tendency for TNFα production by endotoxin-stimulated whole blood to be lower at day 5 post surgery was reported for the fish oil group, but this effect was not significant. Serum IL-6 concentrations were found to be significantly lower at days 0, 1 and 3 post surgery in the fish oil group than in controls. Monocyte expression of human leucocyte antigen DR was shown to be preserved in the fish oil group, but to decline at days 3 and 5 in the control group. No differences in infection rates or mortality were observed. However, post-operative stay in intensive care was found to show a tendency to be shorter in the fish oil group (4·1 d v. 9·1 d in the control group) as did total hospital stay (17·8 d v. 23·5 d in the control group). Post-operative stay on medical wards was reported to be significantly shorter in the fish oil group (P<0·05). Another study has compared the effects of lipid-free total parenteral nutrition or parenteral nutrition including soyabean oil or a mix (%, v/v) of 83 soyabean oil and 17 fish oil from Omegaven for 5 d after large bowel surgery(Reference Schauder, Rohn and Schafer48). No differences were found between the groups in relation to the numbers of circulating lymphocytes, B lymphocytes, helper T lymphocytes, cytotoxic T lymphocytes or natural killer cells before surgery or at days 3 and 6 post surgery, although these variables were affected by surgery itself. Also, no differences were found between groups in relation to T-lymphocyte proliferation, but IL-2 production was increased in the fish oil group and the post-surgery decline in interferon-γ production was prevented by fish oil. It has been reported that length of hospital stay in patients post gastrointestinal surgery is significantly shorter (P=0·006) in patients receiving fish oil (17·2 d) than in the control group (21·9 d)(Reference Wichmann, Thul and Czarnetzki49). In another study of patients post surgery the administration of SMOFLipid for 6 d was shown to result in significantly shorter hospital stay (13·4 d v. 20·4 d; P<0·05) than soyabean oil(Reference Grimm42). Taken together, these studies indicate that inclusion of fish oil in parenteral nutrition regimens for patients who have undergone gastrointestinal surgery modulates generation of inflammatory eicosanoids(Reference Morlion, Torwesten and Lessire43–Reference Grimm, Mertes and Goeters46) and cytokines(Reference Wachtler, Konig and Senkal44, Reference Weiss, Meyer and Matthies47) and may help to counter the surgery-induced decline in antigen-presenting-cell activity(Reference Weiss, Meyer and Matthies47) and production of T-lymphocyte cytokines(Reference Schauder, Rohn and Schafer48). Importantly, these studies do not reveal any deleterious effects of fish oil infusion in these patients. Furthermore, the studies that have examined the hard end point of length of hospital stay suggest a real clinical benefit from fish oil infusion in these patients(Reference Grimm42, Reference Weiss, Meyer and Matthies47, Reference Wichmann, Thul and Czarnetzki49). Another report from a cohort of patients receiving parenteral nutrition post surgery has also indicated the benefit of inclusion of fish oil in the regimen(Reference Tsekos, Reuter and Stehle50). No differences were reported between the control group (MCT–soyabean oil) and the patients receiving fish oil (a mix of Omegaven with a 50:50 (v/v) MCT–soyabean oil mix in which a maximum of one-third of the mix was as fish oil) in relation to the percentage of patients who developed wound infections (6 v. 11 for the fish oil and control groups respectively) or who died (12 v.15 respectively) or in the length of hospital stay (25 d v. 29 d respectively). However, the percentage of patients in the fish oil group who were readmitted to the ICU (5) was shown to be significantly lower (P<0·05) than that in the control group (17). A group of patients also received the fish oil-containing emulsion for 2 d pre-operatively. Here, a number of very significant benefits were found: a significantly decreased need for mechanical ventilation (17% v. 31% in the control group; P<0·05); a significantly shorter length of hospital stay (22 d v. 29 d; P<0·05); significantly less need for readmission to intensive care (5% v. 17%; P<0·05); significantly lower mortality (3% v. 15%; P<0·05)(Reference Tsekos, Reuter and Stehle50). Another study has revealed that intravenous infusion of a lipid emulsion containing (%, w/w) 80 soyabean oil and 20 Omegaven into patients for 5 d following major gastrointestinal surgery accelerates normalisation of liver and pancreatic function compared with soyabean oil alone(Reference Heller, Rossel and Gottschlich51). Overall, no difference was found between the groups in relation to length of stay in the ICU or in hospital. However, in a subgroup of patients at risk of sepsis a reduced ICU stay was reported for the patients receiving fish oil (4·0 d v. 5·3 d for the control group; P=0·01)(Reference Heller, Rossel and Gottschlich51). In a recently published study in which a mixed group of >650 patients, including approximately 230 patients post surgery, received parenteral nutrition including fish oil (Omegaven) for ≥3 d (mean 8·7 d) a significantly lower rate of infections (P<0·0005), fewer complications (P<0·005) and shorter length of hospital stay (P=0·05) were reported in the patients post-surgery receiving fish oil compared with those receiving the control emulsion(Reference Koch and Heller8). Furthermore, infusion of about 0·15 g fish oil/kg per d was shown to decrease mean ICU stay from 8·7 d to 5·3 d and hospital stay from 27·4 d to 25·5 d. Thus, findings available from published studies in patients post gastrointestinal surgery clearly demonstrate clinical benefit from the inclusion of very-long-chain n-3 PUFA in the form of fish oil in parenteral nutrition regimens(Reference Koch and Heller8, Reference Grimm42, Reference Weiss, Meyer and Matthies47, Reference Wichmann, Thul and Czarnetzki49–Reference Heller, Rossel and Gottschlich51). However, a greater benefit has also been demonstrated if these fatty acids are additionally provided pre-surgery, which of course is only possible in elective surgery(Reference Tsekos, Reuter and Stehle50). The greater benefit of pre-operative infusion of long-chain n-3 PUFA most probably relates to better incorporation of the fatty acids into leucocytes and other tissues.
In a recently published study that used MCT–soyabean oil or Lipoplus in patients in the ICU who had undergone abdominal aorta aneurysm repair surgery no differences were found in glucose metabolism or in inflammatory markers(Reference Berger, Tappy and Revelly52). Furthermore, clinical outcomes were not reported to be affected, but a trend was found towards shorter ICU stay (1·6 d v. 2·3 d) and shorter hospital stay (9·9 d v. 11·3 d).
Thus, all three available fish oil-containing lipid emulsions have been used in adult patients post surgery (mainly gastrointestinal). No adverse effects of the use of fish oil have been reported, indicating that it is safe to use for such patients. The use of fish oil is associated with altered patterns of inflammatory eicosanoids and cytokines in patients post gastrointestinal surgery and immune function may be better maintained by fish oil in these patients. Two studies have reported that the use of fish oil is associated with a trend towards reduced length of ICU stay and three studies have reported that fish oil significantly reduces length of hospital stay (two more studies report a trend to reduced length of hospital stay). Lack of significance in studies that report favourable trends may be a result of the small sample size of those studies. Peri-operative administration of fish oil may be superior to post-operative administration. Taken together the studies in patients post surgery present a fairly consistent and positive view of the efficacy of intravenous fish oil administration post surgery. However, in these studies patients who would not normally require parenteral nutrition have frequently been included. Furthermore, the lengths of ICU and hospital stay reported in both control and fish oil groups are frequently much longer than typically seen in many clinical settings. Thus, although the data presently available are highly supportive of the inclusion of fish oil, translation of the findings to the real clinical situation requires further studies designed to mimic current clinical practice; clearly, such studies need to be properly designed and adequately powered.
Studies of fish oil in critically-ill patients
In patients with sepsis who were intolerant of enteral nutrition and received by infusion a standard soyabean oil-based emulsion or an emulsion containing fish oil (Omegaven) for 5 d(Reference Mayer, Fegbeutel and Hattar53) or 10 d(Reference Mayer, Gokorsch and Fegbeutel54) it was reported that blood leucocyte counts and serum C-reactive protein concentration tend to be lower and production of leukotriene B5 by stimulated neutrophils is much higher in patients receiving fish oil(Reference Mayer, Fegbeutel and Hattar53). Production of TNFα, IL-1β, IL-6, IL-8 and IL-10 by endotoxin-stimulated mononuclear cells does not increase during infusion of the fish oil-containing emulsion whereas production of the four pro-inflammatory cytokines is markedly elevated during the first 2 d of soyabean oil infusion(Reference Mayer, Gokorsch and Fegbeutel54). These studies establish that infusion of long-chain n-3 PUFA into patients with sepsis can modulate inflammatory mediator production and related inflammatory processes. It has been demonstrated that this effect might be associated with clinical improvements. In a study of parenteral n-3 PUFA (in the form of Omegaven) infusion that included patients with abdominal sepsis, multiple trauma or severe head injury a significantly lower rate of infection assessed as demand for antibiotics (P<0·001) and shorter lengths of ICU and hospital stay (both P<0·001) were reported for those patients receiving >0·05 g fish oil/kg per d when compared with those receiving <0·05 g fish oil/kg per d(Reference Heller, Rössler and Litz55). Mortality was shown to be significantly decreased (P<0·05) in those patients who received >0·1 g fish oil/kg per d. The survival advantage was found to be greater in some patient groups than others (severe head injury>multiple trauma>abdominal sepsis>non-abdominal sepsis>post surgery), but small numbers of patients in some groups make the interpretation of these data difficult. Furthermore, this study was not controlled or blinded. Nevertheless, these recent data are strongly suggestive of genuine clinical benefit from the inclusion of long-chain n-3 PUFA in parenteral nutrition regimens given to critically-ill patients. This conclusion is in part supported by a recent study of patients with severe acute pancreatitis(Reference Wang, Li and Li56). The patients received soyabean oil or a mixture of soyabean oil and Omegaven for 5 d. Although no differences were found between the groups in relation to inflammatory markers, number of infections or lengths of ICU (27·5 d in the control group v. 21·4 d in the fish oil group) and hospital stay, better gas exchange (P<0·05) and a reduced requirement for continuous renal replacement therapy (P<0·05) was reported for those patients receiving fish oil. In contrast to the generally positive findings from these studies, no differences were found between MCT–soyabean oil and MCT–soyabean oil–Omegaven given over 7 d in medical patients in the ICU in several outcomes, including immune markers, inflammatory markers, bleeding, ventilation requirement, number of infections, length of ICU stay and mortality(Reference Friesecke, Lotze and Köhler57).
Thus, of the three available fish oil-containing lipid emulsions only Omegaven has been used in critically-ill adults. No adverse effects of the use of fish oil have been reported in these studies, indicating that it is safe to use in such patients. The influence of fish oil on inflammatory processes and on immune function in critically-ill patients is not yet clear. Similarly, the impact of fish oil on clinical end points such as infections, length of ICU and hospital stay and mortality is not clear, since there are too few studies and those that are available(Reference Heller, Rössler and Litz55–Reference Friesecke, Lotze and Köhler57) report contradictory findings or do not have a satisfactory design. One important factor, highlighted by one study of parenteral n-3 PUFA from fish oil(Reference Heller, Rössler and Litz55) is the dose of fish oil required to influence clinical outcomes. Overall, the data available are suggestive of some clinical benefit from the inclusion of long-chain n-3 PUFA in parenteral nutrition regimens given to critically-ill patients. However, only limited studies have been published and the inconsistency of findings limits translation to the clinic. Thus, further studies are required; clearly, such studies need to be properly designed and adequately powered.
Summary and conclusions
Lipids traditionally used in parenteral nutrition are based on n-6 PUFA-rich vegetable oils such as soyabean oil. This practice may not be optimal because it may present an excessive supply of linoleic acid. Alternatives to the use of soyabean oil include its partial replacement by MCT, olive oil or fish oil, either alone or in combination. MCT-containing lipid emulsions are well established, but those containing olive oil and fish oil, although commercially available, are still undergoing trials in different patient groups. It is clear that emulsions containing olive oil or fish oil are well tolerated and without adverse effects in a wide range of adult patients. An olive oil–soyabean oil emulsion has been used in quite small experimental studies of critically-ill patients and patients with trauma or burns with little evidence at this stage of advantage over soyabean oil or MCT–soyabean oil. Fish oil-containing lipid emulsions have been used in adult patients post surgery (mainly gastrointestinal). This regimen has been associated with alterations in patterns of inflammatory mediators and in immune function and, in some studies, a reduction in length of ICU and hospital stay. Peri-operative administration of fish oil may be superior to post-operative administration. Fish oil has been used in critically-ill adults. Here, the influence on inflammatory processes, immune function and clinical end points is not clear, since there are too few studies and those that are available report contradictory findings. One important factor is the dose of fish oil required to influence clinical outcomes. Further studies that are properly designed and adequately powered are required in order to strengthen the evidence base relating to the use of lipid emulsions that include olive oil and fish oil in critically-ill patients and post surgery.
Acknowledgements
The author has received speaking fees from B Braun, Fresenius Kabi, and Baxter Healthcare, participated in the Baxter Global Advisory Board in 2008 and has received research funding from B Braun.
